Skip to main content
. 2018 Apr 17;9(29):20426–20438. doi: 10.18632/oncotarget.24921

Table 4. KRAS exon 2 mutations in CD166 positive and CD166 negative CAD.

CAD c.35G>A (G12D) c.35G>T (G12V) c.38G>A (G13D) c.34G>A (G12S) Total
CD166 positive 6/49 (12%) 5/49 (10%) 0/49 (0%) 0/35 (0%) 11
CD166 negative 1/23 (4%) 0/23 (0%) 2/23 (9%) 1/23 (4%) 4
Total 7 5 2 1 15